Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...
SOUTH JORDAN, Utah, March 10, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced enrollment of the first patient in its ...
Twice as many preemies treated with drugs for patent ductus arteriosus died compared to those placed under observation Side effects of drug treatments might have unintended consequences for preemies, ...
Merit Medical Systems, Inc. MMSI, on Monday, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus ...
The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the first medical device to treat patent ductus arteriosus (PDA) in premature babies weighing as little ...
The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...
Doing Nothing Appears Best Approach To Common Heart Defect Among Preemies By Dennis Thompson HealthDay ReporterMONDAY, Dec. 15, 2025 (HealthDay News) — Doing nothing at all to manage a common fetal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback